Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action (NYSE:LLY)

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the liver, BIL showed less activity in peripheral tissues, such as muscle and fat, than insulin glargine.¹ The data will be presented at the 74th American Diabetes Association Scientific Sessions^®.



Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action (NYSE:LLY)